255 related articles for article (PubMed ID: 35580369)
21. Paired comparisons of mutational profiles before and after brachytherapy in asian uveal melanoma patients.
Lee WS; Lee J; Choi JJ; Kang HG; Lee SC; Kim JH
Sci Rep; 2021 Sep; 11(1):18594. PubMed ID: 34545149
[TBL] [Abstract][Full Text] [Related]
22. Metastatic disease in uveal melanoma: importance of a genetic profile?
Van Beek JG; Koopmans AE; Vaarwater J; Verdijk RM; de Klein A; Naus NC; Kiliç E
Melanoma Res; 2015 Oct; 25(5):447-9. PubMed ID: 26086698
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
24. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.
Koopmans AE; Vaarwater J; Paridaens D; Naus NC; Kilic E; de Klein A;
Br J Cancer; 2013 Jul; 109(2):493-6. PubMed ID: 23778528
[TBL] [Abstract][Full Text] [Related]
25. Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.
Versluis M; de Lange MJ; van Pelt SI; Ruivenkamp CA; Kroes WG; Cao J; Jager MJ; Luyten GP; van der Velden PA
PLoS One; 2015; 10(3):e0116371. PubMed ID: 25764247
[TBL] [Abstract][Full Text] [Related]
26. Genetic landscape of uveal melanoma.
Rodrigues MJ; Stern MH
J Fr Ophtalmol; 2015 Jun; 38(6):522-5. PubMed ID: 25976133
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
28. Driver mutations in
García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
[TBL] [Abstract][Full Text] [Related]
29. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
30. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
[TBL] [Abstract][Full Text] [Related]
31. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
32. Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations.
Yavuzyigitoglu S; Mensink HW; Smit KN; Vaarwater J; Verdijk RM; Beverloo B; Brüggenwirth HT; van Marion R; Dubbink HJ; Paridaens D; Naus NC; de Klein A; Kiliç E;
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):2232-9. PubMed ID: 27116551
[TBL] [Abstract][Full Text] [Related]
33. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
34. Patient-derived xenografts recapitulate molecular features of human uveal melanomas.
Laurent C; Gentien D; Piperno-Neumann S; Némati F; Nicolas A; Tesson B; Desjardins L; Mariani P; Rapinat A; Sastre-Garau X; Couturier J; Hupé P; de Koning L; Dubois T; Roman-Roman S; Stern MH; Barillot E; Harbour JW; Saule S; Decaudin D
Mol Oncol; 2013 Jun; 7(3):625-36. PubMed ID: 23478236
[TBL] [Abstract][Full Text] [Related]
35. Uveal melanoma: physiopathology and new in situ-specific therapies.
Souto EB; Zielinska A; Luis M; Carbone C; Martins-Gomes C; Souto SB; Silva AM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):15-32. PubMed ID: 31079217
[TBL] [Abstract][Full Text] [Related]
36. SF3B1 and BAP1 mutations in blue nevus-like melanoma.
Griewank KG; Müller H; Jackett LA; Emberger M; Möller I; van de Nes JA; Zimmer L; Livingstone E; Wiesner T; Scholz SL; Cosgarea I; Sucker A; Schimming T; Hillen U; Schilling B; Paschen A; Reis H; Mentzel T; Kutzner H; Rütten A; Murali R; Scolyer RA; Schadendorf D
Mod Pathol; 2017 Jul; 30(7):928-939. PubMed ID: 28409567
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
Royer-Bertrand B; Torsello M; Rimoldi D; El Zaoui I; Cisarova K; Pescini-Gobert R; Raynaud F; Zografos L; Schalenbourg A; Speiser D; Nicolas M; Vallat L; Klein R; Leyvraz S; Ciriello G; Riggi N; Moulin AP; Rivolta C
Am J Hum Genet; 2016 Nov; 99(5):1190-1198. PubMed ID: 27745836
[TBL] [Abstract][Full Text] [Related]
38. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
39. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.
Möller I; Murali R; Müller H; Wiesner T; Jackett LA; Scholz SL; Cosgarea I; van de Nes JA; Sucker A; Hillen U; Schilling B; Paschen A; Kutzner H; Rütten A; Böckers M; Scolyer RA; Schadendorf D; Griewank KG
Mod Pathol; 2017 Mar; 30(3):350-356. PubMed ID: 27934878
[TBL] [Abstract][Full Text] [Related]
40. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
